Lv1
38 积分 2022-08-16 加入
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
9个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
9个月前
已完结
Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer
1年前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
1年前
已完结
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
1年前
已完结
皖公网安备34019202002308
